tradingkey.logo

葛兰素史克

GSK
49.085USD
+0.125+0.26%
收盘 12/26, 16:00美东报价延迟15分钟
98.81B总市值
13.85市盈率 TTM

葛兰素史克

49.085
+0.125+0.26%

关于 葛兰素史克 公司

GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.

葛兰素史克简介

公司代码GSK
公司名称GSK plc
上市日期May 22, 1972
CEOWaterhouse (Deborah)
员工数量68629
证券类型Depository Receipt
年结日May 22
公司地址980 Great West Road
城市BRENTFORD
上市交易所NASDAQ OMX NASDAQ Basic NYSE
国家United Kingdom
邮编TW8 9GS
电话442080475000
网址https://www.gsk.com/
公司代码GSK
上市日期May 22, 1972
CEOWaterhouse (Deborah)

葛兰素史克公司高管

名称
名称/职务
职务
持股
持股变动
Dr. Hal V. Barron, M.D.
Dr. Hal V. Barron, M.D.
Non-Executive Director
Non-Executive Director
661.21K
+0.43%
Ms. Shobie Ramakrishnan
Ms. Shobie Ramakrishnan
Chief Digital and Technology Officer
Chief Digital and Technology Officer
484.59K
+0.08%
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
38.91K
+0.88%
Ms. Elizabeth McKee (Liz) Anderson
Ms. Elizabeth McKee (Liz) Anderson
Independent Non-Executive Director
Independent Non-Executive Director
3.00K
+0.87%
Dr. Jeannie Lee
Dr. Jeannie Lee
Independent Non-Executive Director and Scientific & Medical Expert
Independent Non-Executive Director and Scientific & Medical Expert
1.58K
+0.83%
Dr. Harry C. (Hal) Dietz
Dr. Harry C. (Hal) Dietz
Independent Non-Executive Director, Scientific and Medical Expert
Independent Non-Executive Director, Scientific and Medical Expert
--
--
Mr. James Ford
Mr. James Ford
Senior Vice President, Group General Counsel, Legal and Compliance
Senior Vice President, Group General Counsel, Legal and Compliance
--
--
Ms. Sally Jackson
Ms. Sally Jackson
Senior Vice President - Global Communications and CEO Office
Senior Vice President - Global Communications and CEO Office
--
--
Dr. Tony Wood, Ph.D.
Dr. Tony Wood, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Julie Brown
Ms. Julie Brown
Chief Financial Officer, Executive Director
Chief Financial Officer, Executive Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Hal V. Barron, M.D.
Dr. Hal V. Barron, M.D.
Non-Executive Director
Non-Executive Director
661.21K
+0.43%
Ms. Shobie Ramakrishnan
Ms. Shobie Ramakrishnan
Chief Digital and Technology Officer
Chief Digital and Technology Officer
484.59K
+0.08%
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
38.91K
+0.88%
Ms. Elizabeth McKee (Liz) Anderson
Ms. Elizabeth McKee (Liz) Anderson
Independent Non-Executive Director
Independent Non-Executive Director
3.00K
+0.87%
Dr. Jeannie Lee
Dr. Jeannie Lee
Independent Non-Executive Director and Scientific & Medical Expert
Independent Non-Executive Director and Scientific & Medical Expert
1.58K
+0.83%
Dr. Harry C. (Hal) Dietz
Dr. Harry C. (Hal) Dietz
Independent Non-Executive Director, Scientific and Medical Expert
Independent Non-Executive Director, Scientific and Medical Expert
--
--

收入明细

单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
由于公司未披露,未能获取相关数据
地区USD
名称
营收
占比
US
5.49B
51.53%
Rest of world
2.71B
25.44%
Europe
2.45B
23.03%
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 11月15日 周六
更新时间: 11月15日 周六
持股股东
股东类型
持股股东
持股股东
占比
Dodge & Cox
3.85%
Fidelity Management & Research Company LLC
2.74%
Fisher Investments
1.58%
PRIMECAP Management Company
1.26%
JTC Employer Solutions Trusteee Ltd
0.72%
其他
89.85%
持股股东
持股股东
占比
Dodge & Cox
3.85%
Fidelity Management & Research Company LLC
2.74%
Fisher Investments
1.58%
PRIMECAP Management Company
1.26%
JTC Employer Solutions Trusteee Ltd
0.72%
其他
89.85%
股东类型
持股股东
占比
Investment Advisor
9.60%
Investment Advisor/Hedge Fund
7.49%
Research Firm
1.05%
Hedge Fund
0.80%
Bank and Trust
0.10%
Individual Investor
0.06%
Pension Fund
0.06%
Family Office
0.03%
Family Office
0.02%
其他
80.79%

机构持股

更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
1474
388.63M
19.14%
-11.70M
2025Q2
1478
378.08M
18.54%
+5.70M
2025Q1
1494
378.46M
18.50%
+5.08M
2024Q4
1481
355.06M
17.14%
+27.38M
2024Q3
1472
319.97M
15.44%
-30.07M
2024Q2
1585
322.06M
15.54%
-29.11M
2024Q1
1617
318.91M
15.39%
-23.52M
2023Q4
1614
299.81M
14.57%
-35.71M
2023Q3
1570
293.92M
14.35%
-37.46M
2023Q2
1545
286.58M
13.99%
-41.88M
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
Dodge & Cox
78.76M
3.87%
+106.04K
+0.13%
Jun 30, 2025
Fidelity Management & Research Company LLC
51.48M
2.53%
+872.19K
+1.72%
Jun 30, 2025
Fisher Investments
31.34M
1.54%
+1.31M
+4.35%
Jun 30, 2025
PRIMECAP Management Company
27.73M
1.36%
+2.02M
+7.85%
Jun 30, 2025
JTC Employer Solutions Trusteee Ltd
15.00M
0.74%
-262.98K
-1.72%
Jun 30, 2025
Fidelity Institutional Asset Management
9.53M
0.47%
+10.84K
+0.11%
Jun 30, 2025
T. Rowe Price International Ltd
8.05M
0.4%
+324.11K
+4.20%
Jun 30, 2025
RBC Capital Markets Wealth Management
6.99M
0.34%
+740.61K
+11.84%
Jun 30, 2025
Holocene Advisors, LP
5.61M
0.28%
+304.49K
+5.74%
Jun 30, 2025
State Street Investment Management (US)
6.71M
0.33%
-258.77K
-3.71%
Jun 30, 2025
查看更多

持股ETF

更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
VanEck Pharmaceutical ETF
10.83%
The Opal International Dividend Income ETF
4.41%
Sound Equity Dividend Income ETF
3.97%
Keating Active ETF
3.88%
USCF Dividend Income Fund
3.83%
Brandes International ETF
2.87%
Altrius Global Dividend ETF
2.58%
Fidelity Blue Chip Value ETF
1.6%
Lattice Hartford Mltfctr Dev Mkts (ex-US) Str ETF
1.17%
Avantis International Large Cap Value ETF
1.02%
查看更多
VanEck Pharmaceutical ETF
占比10.83%
The Opal International Dividend Income ETF
占比4.41%
Sound Equity Dividend Income ETF
占比3.97%
Keating Active ETF
占比3.88%
USCF Dividend Income Fund
占比3.83%
Brandes International ETF
占比2.87%
Altrius Global Dividend ETF
占比2.58%
Fidelity Blue Chip Value ETF
占比1.6%
Lattice Hartford Mltfctr Dev Mkts (ex-US) Str ETF
占比1.17%
Avantis International Large Cap Value ETF
占比1.02%

分红派息

近5年累计派现 20.79B 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
Feb 05, 2025
GSK.NB Interim Cash Dividend of gross USD 0.434774 paid on Jul 10, 2025 going ex on May 16, 2025
May 16, 2025
Jul 10, 2025
May 16, 2025
Feb 05, 2025
GSK.NB Interim Cash Dividend of gross USD 0.42996 paid on Oct 09, 2025 going ex on Aug 15, 2025
Aug 15, 2025
Oct 09, 2025
Aug 15, 2025
Feb 05, 2025
GSK.NB Approximate final Cash Dividend of gross USD 0.417088 paid on Jan 08, 2026 going ex on Nov 14, 2025
Nov 14, 2025
Jan 08, 2026
Nov 14, 2025
Feb 05, 2025
GSK.NB Interim Cash Dividend of gross USD 0.407568 paid on Apr 10, 2025 going ex on Feb 21, 2025
Feb 21, 2025
Apr 10, 2025
Feb 21, 2025
Oct 30, 2024
GSK.NB Final Cash Dividend of gross USD 0.376892 paid on Jan 09, 2025 going ex on Nov 15, 2024
Nov 15, 2024
Jan 09, 2025
Nov 15, 2024
Jul 31, 2024
GSK.NB Interim Cash Dividend of gross USD 0.392813 paid on Oct 10, 2024 going ex on Aug 16, 2024
Aug 16, 2024
Oct 10, 2024
Aug 16, 2024
May 01, 2024
GSK.NB Interim Cash Dividend of gross USD 0.384301 paid on Jul 11, 2024 going ex on May 16, 2024
May 17, 2024
Jul 11, 2024
May 16, 2024
Feb 01, 2024
GSK.NB Interim Cash Dividend of gross USD 0.404885 paid on Apr 11, 2024 going ex on Feb 22, 2024
Feb 23, 2024
Apr 11, 2024
Feb 22, 2024
Nov 01, 2023
GSK.NB Interim Cash Dividend of gross USD 0.356356 paid on Jan 11, 2024 going ex on Nov 16, 2023
Nov 17, 2023
Jan 11, 2024
Nov 16, 2023
Jul 26, 2023
GSK.NB Interim Cash Dividend of gross USD 0.343532 paid on Oct 12, 2023 going ex on Aug 17, 2023
Aug 18, 2023
Oct 12, 2023
Aug 17, 2023
查看更多

拆合股

公告日期
类型
比率
Jun 24, 2022
Merger
5→4
Jun 24, 2022
Merger
5→4
Jun 24, 2022
Merger
5→4
Jun 24, 2022
Merger
5→4
公告日期
类型
比率
Jun 24, 2022
Merger
5→4
Jun 24, 2022
Merger
5→4
Jun 24, 2022
Merger
5→4
Jun 24, 2022
Merger
5→4

常见问题

葛兰素史克的前五大股东是谁?

葛兰素史克 的前五大股东如下:
Dodge & Cox持有股份:78.76M,占总股份比例:3.87%。
Fidelity Management & Research Company LLC持有股份:51.48M,占总股份比例:2.53%。
Fisher Investments持有股份:31.34M,占总股份比例:1.54%。
PRIMECAP Management Company持有股份:27.73M,占总股份比例:1.36%。
JTC Employer Solutions Trusteee Ltd持有股份:15.00M,占总股份比例:0.74%。

葛兰素史克的前三大股东类型是什么?

葛兰素史克 的前三大股东类型分别是:
Dodge & Cox
Fidelity Management & Research Company LLC
Fisher Investments

有多少机构持有葛兰素史克(GSK)的股份?

截至2025Q3,共有1474家机构持有葛兰素史克的股份,合计持有的股份价值约为388.63M,占公司总股份的19.14%。与2025Q2相比,机构持股有所增加,增幅为0.60%。

哪个业务部门对葛兰素史克的收入贡献最大?

在FY2025Q2,--业务部门对葛兰素史克的收入贡献最大,创收--,占总收入的--%。
KeyAI